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Abstract
Introduction: This study analyze factors associated to cannabis use in pregnant women, its perceived availability, its
risk perception and the relationship between prenatal exposure to cannabis and developmental and mental
disorders.
Objectives: We present a review of the literature on cannabis use among pregnant women. The objective is to
analyze factors associated to cannabis use during pregnancy and assess the potential effects of prenatal exposure
to cannabis on the development of the fetus and the mental health of those exposed.
Methods: Systematic review of studies on the maternal use of cannabis and the relationship between early
exposure and the development of psychiatric disorders in the PubMed database until July 2018 in English and
Spanish with the following keywords: Marijuana, Cannabinoids, Mental disorders, Pregnancy, Prenatal Cannabis
Exposure, Risk factors.
Results: The use of cannabis among pregnant women is frequent but it has not been extensively researched.
Prenatal exposure to cannabis may be associated with affective symptoms and ADHD.
Conclusions: Mental healthcare professionals who treat women during their fertile life need to be able to explain
the relationship between prenatal exposure to cannabis and the presence of developmental and mental disorders.
Keywords: Cannabis, Mental disorders, Pregnancy, Prenatal Cannabis exposure, Risk factors, Prenatal marijuana
exposure
Plain English summary
Cannabis is the most consumed illegal drug in Europe.
Substance abuse in pregnant women has increased over
the past decades. Cannabis use during pregnancy is
underdetected.
The objective of this review is to analyze factors asso-
ciated to cannabis use during pregnancy and assess the
potential effects of prenatal exposure to cannabis on the
development of the fetus and the mental health of those
exposed.
After conducting a search on the main online database
and studying the available literature, we found that can-
nabis use during pregnancy may be associated with ab-
normalities in general development, as well as with
changes in brain chemistry both in humans and in re-
search animals. Furthermore, exposure to cannabis dur-
ing pregnancy may be associated with the development
of mental disorders such as Attention Deficit Hyper-
activity Disorder (ADHD) and depression.
Early detection and alerting pregnant women about
the risks of cannabis use during pregnancy is one way to
minimize its possible harm. Therefore, we need to
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: croncero@saludcastillayleon.es
1Psychiatric Service, University of Salamanca Health Care Complex,
Salamanca, Spain
2Institute of Biomedicine of Salamanca (IBSAL), University of Salamanca,
Salamanca, Spain
Full list of author information is available at the end of the article
Roncero et al. Reproductive Health           (2020) 17:25 
https://doi.org/10.1186/s12978-020-0880-9
expand our scientific knowledge and to train health pro-
fessionals in this field.
Introduction
Cannabis is the most widely used illegal drug in Spain
and in Europe [1]. According to the EMCDDA (Euro-
pean Monitoring Centre for Drugs and Drug Addiction),
26.3% of all Europeans have tried cannabis throughout
their lives and 7.2% have used it in the last year, with a
prevalence of use at 14.1% among young adults between
18 and 35 years [1].
In Spain and most of Europe, cannabis continues to be
an illegal substance, however, there are some regions in
the western world where this has changed as some states
of United States. Recently, other countries like Uruguay,
or more recently, Canada have legalized their consump-
tion [2].
In Spain, the average age of first cannabis use is 18.3
years [2], although the main age group is the population
of ages 15 to 24, in which 19.9% reports having used
cannabis in the last 12 months [2]. This finding is in line
with the European School Survey Project on Alcohol
and Other Drugs (ESPAD), which includes information
on substance use among 15- to 16-year-old students in
35 European countries. In the group of 24 Member
States of the EU plus Norway, 18% of the students re-
ported having tried cannabis at least once (lifetime
prevalence); the highest levels were observed in the
Czech Republic (37%) and France (31%); and 8% said
that they had used cannabis in the last month [1].
In the 14–18 age group, the Secondary School Survey
on Drugs in Spain (ESTUDES, 1994–2016) [2] was car-
ried out, and it confirmed that the most commonly used
illegal substance in Spain is cannabis, with an average
age of 14.9 years for first use. Given its prevalence
among adolescents and young adults, we can say that
the use of cannabis has a large impact nowadays. In
addition, the risk perception among the young popula-
tion is lower than with other drugs [2]. Young people
have a low perception of the risk associated to the use of
cannabis, in spite of all the available evidence about its
physical, psychological and social consequences. Canna-
bis is the most widely available psychoactive substance
after alcohol and tobacco [2].
Differences are observed in substance use between
men and women [2]. The use of legal drugs is more
widespread among women and the use of all illegal
drugs is more prevalent among men. The differences in
prevalence based on gender decrease with decreasing
age, since in the population aged 14–18 almost no dif-
ferences regarding gender were found [2]. However, the
gender inequality decreased in the 1996–2009 period
[1], and all the prevalence indexes increased for women
[2], particularly young women of fertile age.
There are very few data on pregnant women that let
us deduce the real prevalence of use; however, the ana-
lysis of the meconium of newborns from mothers who
gave birth in Spanish public hospitals revealed cannabis
in 5.3% of the cases [3], a figure which is similar to what
was found in other international studies (4.5% of all
pregnancies).
Volkow describes that in the US between 2002 and
2003 and 2016–2017, adjusted prevalence of past month
cannabis use increased from 3.4 to 7.0% among pregnant
women [4]. Cannabis was the illegal drug most com-
monly consumed by pregnant women in western coun-
tries [3, 5, 6].
However, there are some challenges in cannabis detec-
tion, derived from under-reporting, the fear of legal con-
sequences, the possible loss of the children’s custody,
and the feelings of guilt caused by the potential effects
on the baby.
The use of cannabis in pregnancy is very relevant for
its effects on the development of the fetus may be subtle
at first and not be detectable for many months to years
after birth, but the physical and psychopathological con-
sequences on the adult life may be severe. Evidence on
these effects is plentiful but ambiguous [5].
For this reason, the objective of this study is to review
the literature on the use of cannabis among pregnant
women, its associated factors and its potential effects on
the development of the fetus during the postnatal
period, childhood and adolescence.
Material and methods
A search in English and Spanish was carried out on the
PubMed database for matches until July 2018 with the
following keywords: “Marijuana”, “Cannabis”, “Cannabi-
noids”, “Mental disorders”, “Pregnancy”, “Prenatal Can-
nabis Exposure”, “Risk factors”, “Prenatal Marijuana
Exposure”. The keywords were combined as follows:
“Prenatal Cannabis exposure”; “Prenatal Marijuana ex-
posure”; “Prenatal Cannabis exposure” AND Pregnancy
AND Marijuana AND Cannabinoids; “Prenatal Cannabis
exposure” AND Pregnancy AND Marijuana AND “Men-
tal disorders”; “Prenatal Cannabis exposure” AND Preg-
nancy AND Marijuana AND “Risk factors”; Pregnancy
AND Cannabis.
The inclusion criteria were: studies specifically focused
on associated factors of cannabis use during pregnancy,
effects of exposure to cannabis on the developing fetus
and its mental health.
The search revealed 491 potentially adequate articles,
377 of which did not meet the inclusion criteria after a
review of their title and their abstract. One hundred
fourteen articles were selected, 73 of which were ruled
out after a full reading. Ultimately, 41 articles from the
original search were included [3, 5–44], plus 25 articles
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which were added after appearing repeatedly in the list
of references of the first group [1, 2, 4, 45–66]. Accord-
ing to the PRISMA methodology [63], 73 articles were
ruled out because of a small sample size, unclear designs
or methods of study, not addressing review objectives or
not specific information about cannabis. Fig. 1.
The review includes 4 articles that focus on the preva-
lence of prenatal exposure to cannabis [3, 5, 6, 45], 7 ar-
ticles that discuss detection methods for the use of
drugs in pregnant women [7–12, 46], 9 molecular stud-
ies [13–20, 47], 6 studies on rodents [21–25, 48] and 33




This section describes the results of the review of articles
on associated factors to cannabis use during pregnancy
and on the prenatal exposure to cannabis and its pos-
sible relationship with developmental disorders and/or
psychopathological consequences.
Factors associated to cannabis use during pregnancy
Heterogeneous results have been obtained from different
studies, this is probably related to differences in sample
populations, study designs used and cultural differences
from the geographical locations in which these studies
are carried out.
El Marroun et al. can not find any strong association
with demographic characteristics as age, ethnicity or
presence of psychopathology with cannabis use during
pregnancy in the study he performed in Rotterdam. But
it is described a strong association with biological fa-
ther’s cannabis use and being unmarried. Religion is de-
scribed as a protective factor. From this sample 3′2% of
women used cannabis before being pregnant, 2′9% be-
fore and during pregnancy, but just 0′6% of women de-
cided to continue cannabis use throughout pregnancy.
This last group had a lower educational level [6].
They also find out that history of cannabis addiction
makes 2.77 times more likely to continue cannabis use
during pregnancy; also, women with a frequent cannabis
use (daily or weekly) are more likely to continue it than
those who use it monthly [6].
However, Gray et al., in a study performed in US, can-
not describe strong association with demographic char-
acteristics as age, being unmarried or being employed. It
is described that Hispanic women are less likely to use
cannabis during pregnancy, but cannabis use was more
likely in women from multiracial origin [9]. This differs
Fig. 1 Review Flowchart
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from another study conducted in the US in which an as-
sociation is found between cannabis use during preg-
nancy and characteristics such as being young,
unmarried and non-Hispanic white. It is associated with
having a psychiatric disease different from substance ad-
diction and not having graduated from high school [65].
The knowledge of these associated factors to cannabis
use during pregnancy may be useful in order to identify
future mothers to provide with quality information
about the possible consequences of prenatal exposure to
cannabis [66].
Animal studies on the effects on children of prenatal
cannabis exposure
In animal models, controlled doses of cannabinoids were
administered to pregnant or very young animals. After-
wards, the studies assessed the effects on the develop-
ment of the CNS, the neurotransmission systems, the
appearance or enhancement of drug-seeking behavior,
the presence of altered behavior and the psychomotor
skills, in order to infer the presence of the equivalent to
“mental disorders” in animals [21–25, 48]. The use of
cannabis in rats causes changes in the dopaminergic ac-
tivity of the corpus striatum which leads to attention
deficit and hyperactivity disorders and alterations in
locomotion [21], and on the prefrontal cortex, which
causes cognitive impairment and emotional dysregula-
tion. Prenatal exposure in rodents causes an increased
rate of ultrasonic vocalizations when separated from the
mother, which leads to increased levels of anxiety that
are related to the presence of CB1 receptors in the cor-
tex, the hippocampus, the lateral septum, the nucleus ac-
cumbens and the amygdala, which regulate the release
of 5-HT, dopamine, CCK and CRF, which are anxiogenic
peptides [13, 21].
In addition, changes take place in the dopaminergic
activity of the hypothalamic–pituitary axis and the
amygdala, which are involved in emotion regulation [13].
It has been observed that the exposure of rats to low or
moderate doses of the cannabinoid agonist WIN 55,
212–2 causes permanent alterations in the cortical gluta-
matergic system and affects the migration of glutamater-
gic neurons and GABAergic interneurons [22, 23].
Exposure to this agonist induces alterations in the intrin-
sic electrophysiological properties of the Purkinje neu-
rons of the cerebellum and causes alterations in the
motor and exploratory activity [24]. Alterations of
endorphins and an enhancement of opioid-seeking
behavior have been described mainly in female rats [21,
48]. However, there is controversy as to whether
exposure to THC in adolescent animals alters opioid
reinforcement in the adult life [26] and increases the
self-administration of heroin [26, 48] (Table 1). The
evidence suggests that, in animals, there are persistent
changes after the use of cannabis regarding behavior,
motivation, the reinforcement caused by drugs and
the response to stress [48].
Human studies on the effects on children of prenatal
cannabis exposure’
The mechanisms through which cannabis affects the
brain of the human fetus and causes neurochemical and
neuroanatomical changes are not well known. Cannabin-
oid receptors are present in the placenta and they appear
in the fetal brain at 14 weeks after conception and in-
crease in density throughout the third trimester. Given
its lipophilic nature, one third of the THC in the mater-
nal plasma crosses the placenta and it can be excreted
into breastmilk. Cannabis could alter the function of
fetal cannabinoid receptors [14, 26] and it may lead to
changes in the dopaminergic and opioid system [15, 16].
Table 1 Described consequences of Perinatal Cannabis Exposure in Humans and Rodents
Humans Rodents
System - alterations on the mesocorticolimbic system [15, 16].
- thicker prefrontal cortex [43].
- changes in the dopaminergic activity of the corpus striatum and on the
prefrontal cortex [21].
- dopaminergic activity of the hypothalamic–pituitary axis and the amygdala
[13].
- alterations in the cortical glutamatergic system and affects the migration of
glutamatergic neurons and GABAergic interneurons [22, 23].
- alterations in the intrinsic electrophysiological properties of the Purkinje
neurons of the cerebellum [24].
Molecular - high CB1 mRNA expression in the fetal hippocampus and
amygdala [15].
- decrease in the expression of proenkephalin mRNA in the
fetal striatum with a dose-dependent effect [20, 47].
- up-regulation of proenkephalin mRNA in the mesolimbic area
in adult life [20, 47].
- increased expression of u-opioids in the amygdala [17–20,
47].
- decrease of k-opioid receptor mRNA in the mid-dorsal thal-
amus [17–20, 47].
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There is a high density of cannabinoid receptors in the
frontal lobe and the cerebellum, and these structures
show a parallel and late maturation when compared with
other structures of the brain [25]. Studies on the expos-
ure of human fetuses to cannabis have reported alter-
ations and a different impact on the mesocorticolimbic
system, which is in charge of the regulation of emotions
[15, 16]. The CB1 receptor has been associated with the
dopaminergic and opioid systems (neuropeptidase) [15],
and it has been hypothesized that an increase of its ex-
pression in the hippocampus and amygdala of the fetus
may suggest that these structures are more vulnerable to
prenatal exposure to cannabis [15].
Intrauterine exposure to cannabis may causes different
pattern of the anatomical organization of the CB1
mRNA expression in the mid-gestation fetal and adult
human brain; has been found high CB1 mRNA expres-
sion in the fetal hippocampus and amygdala [15], a de-
crease in the expression of proenkephalin mRNA in the
fetal striatum with a dose-dependent effect [20, 47], and
an up-regulation of proenkephalin mRNA in the meso-
limbic area in adult life [20, 47]. There is also an in-
creased expression of u-opioids in the amygdala and a
decrease of k-opioid receptor mRNA in the mid-dorsal
thalamus [17–20, 47]. This all suggests that in utero ex-
posure to cannabis fundamentally changes the systems
that regulate the emotional life, such as the mesocortico-
limbic pathway, and these changes may even be persist-
ent in this individuals [17, 20, 47].
There is one study that assess the different conse-
quences of the maternal use of cannabis in the new-
born [9]. From a somatic perspective, the use of
cannabis has been associated, both in the early and
the late stages of pregnancy, with a higher risk of re-
stricted fetal growth [9], low birth weight, a shorter
birth length and a low head circumference [18, 27,
58, 59], hypertelorism, and epicanthus [9, 56]. From a
cardiovascular perspective, an association has been
observed with ventricular septal defect [28]. The in
utero exposure to cannabinoids may result in a dys-
function of the T lymphocytes and a decreased im-
mune response to viral antigens. These effects may be
mediated by epigenetic mechanisms such as alter-
ations of micro RNA, DNA methylation and modifica-
tion of histone profiles. Therefore, prenatal exposure
to cannabis may cause epigenetic changes that could
have consequences on the later development or even
long-term transgenerational effects [29]. In children
who were exposed to cannabis in the prenatal stage, a
thicker prefrontal cortex was observed when com-
pared with non-exposed children [43] (Table 1).
From a psychiatric perspective, cannabis withdrawal
syndrome has been described in newborns [9], although
other authors have been unable to prove the existence of
negative perinatal effects in children whose mothers
used cannabis [58].
There are few review studies suggesting prenatal ex-
posure to cannabis may be associated with mood and
behavioral alterations, that could be related with
affective mental disorders, and depressive symptoms, as
well as ADHD [19, 31–34]. There are no studies that es-
tablish a connection with the presence of psychotic dis-
orders [35].
There are longitudinal studies which describe behav-
ioral and cognitive disorders associated with uterine ex-
posure to cannabis, such as the Ottawa Prenatal
Prospective Study [60] and the Maternal Health Prac-
tices and Child Development Project [36]. These studies
did not find significant behavioral alterations in the new-
borns whose mothers used cannabis, but they observed
that they sleep fewer hours and show habituation deficit
to visual stimuli [36, 37, 61]. At age two, no cognitive al-
terations have been found on those children [38]. At age
three, an alteration of short-term memory has been ob-
served on verbal and abstract reasoning and on verbal
skills, without any effect on intelligence [38].
The study carried out by Day et al. (2011) describes
the association between prenatal exposure to cannabis
and a low IQ during the school age [39]. An alteration
of the executive functions regulated by the prefrontal
cortex has also been described [32], including visual-
spatial reasoning, response inhibition and working mem-
ory, which may last until ages 13–16 [32]. At these ages,
the children may present higher impulsiveness and
hyperactivity, lower attention capacity and a higher
prevalence of delinquent behavior, which could be par-
tially related to the alterations mentioned above [39].
Have been observed in two studies that the executive
dysfunction could be present even into early adulthood
[37, 40]. On the other hand, an increase in the use of
cannabis and nicotine at ages 14–21 has been observed
among individuals who had been exposed during the
prenatal stage, particularly in men [37, 40]. Another lon-
gitudinal study, The Generation R Study [62], still on-
going, has observed an association between the maternal
use of cannabis and an increase in aggressive behavior
and attention disorders in girls at 18 months of age, and
this association stops being statistically significant at
36 months [42, 62]. At 30 months, no differences
were found in the nonverbal cognitive scales or in
language development, regardless of sex [62]. Finally,
a recent study establishes an association between the
maternal use of alcohol and cannabis and Tourette
syndrome [44].
A maternal questionnaire could not be considered an
efficient screening tool for the detection of the maternal
use of cannabis one of the reasons is the underreporting
among pregnant women [11, 12, 46, 66], which justifies
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the need to use biomarkers [8]. Both the use of maternal
hair and the meconium of the newborn have shown a
prevalence of substance use that is higher than what was
detected through clinical interviews [8].
Maternal hair provides direct information on THC use
over the last months, or even years [8]. It offers a direct
estimation of maternal exposure to drugs, but only an
indirect estimation of the substances that reach the fetus
through the placenta.
Meconium is the most widely used fetal matrix to re-
veal prenatal exposure to drugs of abuse [6]. It can be
easily obtained, but it has a collection window of 72 h, it
could be less sensitive for detection of exposure during
the first trimester and testing is more expensive and less
available [7, 8]. Screening of blood and urine samples
during pregnancy is simpler and more readily available,
but it only provides information about substance use
over the last 24–48 h [10, 46].
Discussion
There is a high prevalence of cannabis use during preg-
nancy, despite the difficulties to detect its consumption
among pregnant women. However, it is difficult to de-
scribe factors associated to cannabis use during preg-
nancy due to the different results obtained in different
studies. While in EU, El Marroun et al. associates being
unmarried and lower education level as more likely in
women that use cannabis during pregnancy, no associ-
ation is found with demographic characteristics as age,
employment or ethnicity [6]. In US, Martin et al. finds
association with young age, not unemployed and white
non-Hispanic women, this study also find association
with being unmarried and having lower educational level
[65]. This also differ from other US study, which finds as
more likely cannabis use during pregnancy women from
multiracial origins, but no differences with age, employ-
ment or marital status [9]. This heterogeneity in findings
across studies could be explained with the differences in
study designs used, confounding factors, sample popula-
tion and sample size.
In humans, the endocannabinoid system appears at an
early stage of the embryonic and fetal development, and
it is related to the development of other neurotransmis-
sion systems (opioid, glutamatergic, dopaminergic, sero-
toninergic, etc.), which may be affected by exposure to
cannabis. Prenatal exposure to cannabis could cause al-
terations of the activity of brain areas such as the pre-
frontal cortex, the mesolimbic system, the striatum and
the hypothalamic-pituitary axis, which are involved in
executive functions and the reinforcement and regula-
tion of the emotional systems. So according to this hy-
pothesis there could be neuro-cognitive consequences to
the exposure, some of which may remain present even
in early adulthood, such as executive dysfunction, with
repercussions on the daily life [15, 16, 64].
It may exists relationship between prenatal exposure to
cannabis and the presence of neurocognitive [32, 38, 40,
44] and psychiatric consequences in adult life, particularly
regarding affective disorders (anxiety and depression) [13,
31, 32] and ADHD [31, 32, 34, 46], as well as emotional
dysregulation, cognitive alterations and an alteration of
opioid reinforcement. This last effect has been observed in
studies on rodents [10, 19, 25, 31–34, 48].
It is necessary to point out that there are multiple
methodological limitations in the studies in our review.
We may highlight the reduced sample sizes [35]; limita-
tions in the screening methods for the detection of sub-
stance use [11, 46], of the dose, and of the time of
exposure during pregnancy; and the variability of the
type and composition of the marijuana that was used
[34], as well as the simultaneous use of other substances,
including nicotine [9]. Similarly, there are few longitu-
dinal prospective studies on this topic [12, 36, 60, 62].
Therefore, it is difficult to establish a clear association
between exposure to cannabis during pregnancy and the
potential alterations on a neurochemical and neuroana-
tomical level, as well as the perinatal consequences and
the presence of cognitive alterations or mental disorders
in the child, the adolescent and the adult individuals.
However, although some limitations have been described
in the different studies, we can state that the use of can-
nabis among pregnant women is a common occurrence,
but underreported and underdetected [66]. In the stud-
ies of drug use among pregnant women, the maternal
questionnaire is not an effective detection tool due to
underreporting by the mothers, often caused by fear of
legal consequences, fear of losing the custody of the chil-
dren, or a feeling of guilt because of the potential effects
on the health of the newborn. Also, due to the condi-
tions in which the interview takes place, lack of precision
regarding the moment of gestation in which they used
cannabis or the amount they used [11, 12, 46]. This may
justify the use of biomarkers [8].
Both maternal hair and the meconium of the newborn
have shown a prevalence of substance use that is higher
than what was detected through clinical interviews [8].
Hair samples have been considered the reference bio-
logical matrix to assess the chronic use of drugs during
pregnancy. It involves a noninvasive procedure, a consid-
erable amount can be obtained, and it allows a retro-
spective study over a longer period. Meconium samples
are easy to collect and parental agreement is generally
easily obtained. However, it has a short collection win-
dow (under 72 h), testing is more expensive and less
available [7, 8]. Therefore, screening with blood and
urine samples is used during pregnancy because it is eas-
ier and more readily available, in spite of the fact that
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these tests only provide information about use in the last
24–48 h [10, 46]. There are few studies using detection
methods, each of them with different methods and de-
signs. More homogeneously design studies are needed in
order to develop sensitive and available methods for sub-
stance use detection.
Healthcare professionals play an essential role both in
psychoeducational counseling, awareness and prevention
initiatives, and in the early detection of cannabis use and
the diagnosis and treatment of cannabis abuse and de-
pendence. It is important for these professionals to have
up-to-date knowledge on early exposure in order to in-
form the patients about the possible consequences, so
that they can develop the necessary interventions in sus-
ceptible populations [66].
Conclusions
The use of cannabis during pregnancy could produce
neurochemical alterations both in humans and in re-
search animals. From a clinical perspective, medical and
psychiatric alterations have been described both in
cross-sectional and in cohort studies.
Althoght there is some controversial findings, some re-
gional differences and there are methodological limita-
tions of the studies, early detection is fundamental. It is
also important to warn women about the risks of using
cannabis during pregnancy in order to minimize the
possible consequences, which mainly include affective
disorders and ADHD and which depend on duration
and intensity of the prenatal exposure. In this regard,
awareness campaigns may be an essential tool.
An active involvement is required from primary care,
obstetricians, pediatric, mental health and drug depend-
ence services. Longitudinal prospective studies need to
be designed to finally identify all the consequences of
prenatal exposure to cannabis regarding developmental
alterations, neuro-cognitive side effects and mental dis-
orders among the exposed population.
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